Acid-fast bacillus (AFB) spinal osteomyelitis in a patient with AIDS is often presumed to be caused by reactivated Mycobacterium tuberculosis. However, other AFB pathogens can mimic M. tuberculosis and, to ensure appropriate and adequate therapy, should be considered by clinicians. We present a case of aggressive spinal osteomyelitis caused by Mycobacterium heckeshornense in an AIDS patient; a review of the literature is also included.

CASE REPORT

A 45-year-old man with AIDS presented with a 3-week history of mid-back pain. There was no history of trauma or constitutional or neurologic symptoms. He also had a history of pulmonary cryptococcosis, Kaposi's sarcoma, squamous cell carcinoma of the skull and face, chronic hepatitis B infection, and medication nonadherence. Medications included fosamprenavir, ritonavir, tenofovir, lamivudine/zidovudine, rilpivirine, prophylactic atovaquone and azithromycin, and fluconazole. Physical examination revealed normal vital signs without fever, low thoracic spine midline tenderness without overlying edema, erythema, ecchymosis, or mass lesion, and normal neurologic exam. Laboratory data included a total white blood count of 3.5 × 10^3/µl, hemoglobin of 11.4 g/dl, hematocrit of 36.4%, platelet count of 297 × 10^3/µl, creatinine of 0.7 mg/dl, normal liver enzymes, an HIV load of 25 copies/ml, and a CD4 lymphocyte count of 65 cells/µl (3%). Magnetic resonance imaging revealed a 2.1-cm by 2.5-cm by 2.0-cm low T1 and bright T2 bone marrow lesion of the T12 and L1 vertebral bodies involving the T12/L1 disk (Fig. 1). A computerized tomography (CT)-guided biopsy of the L1 lesion was obtained; aerobic, anaerobic, and fungal cultures showed no growth, but an acid-fast bacillus (AFB) smear was positive. For presumed diagnosis of spinal tuberculosis, rifabutin (dosed by blood levels), isoniazid, pyrazinamide, and ethambutol (RHZE) were initiated; the rilpivarine dose was doubled. Eighteen days later, an orange-pigmented growth was noted in a BacT/Alert MP bottle (bioMérieux, Durham, NC) incubated at 37°C on the BacT/Alert 3D system. Preliminary rRNA-DNA hybridization of the bottle sediment (AccuProbe, Gen-Probe, Inc., San Diego, CA) was positive for Mycobacterium gordonae (36,271 relative light units) and negative for Mycobacterium avium complex (MAC) (<10,000 RLU). Given the clinical presentation consistent with tuberculous mycobacterium disease and a probe value just above the assay cutoff (30,000 RLU), DNA probes were repeated on growth on Lowenstein-Jensen (LJ) slants and were negative for M. gordonae (<10,000 RLU) and also negative for M. tuberculosis (MTB) complex. A final probe set of the bottle sediment was negative for M. gordonae, MTB complex, and MAC, suggesting that the initial result was a false-positive result for M. gordonae. Biochemically, the isolate was scotochromogenic, reactive for aryl sulfatase at 14 days, and nonreactive for nitrate reduction, semiquantitative catalase, heat-stable (68°C) catalase, urease, and Tween hy-
drolysis. Despite strong biochemical similarity to *Mycobacterium xenopi*, the isolate grew equally well at 37°C and 42°C. The isolate was sent for molecular identification by 16S rRNA gene sequencing and identified as *Mycobacterium heckeshornense*; there was 100% identity with *M. heckeshornense* over a match length of 986 bp, while there were 36 mismatches with the next closest match, *M. xenopi*. The identification was performed at a large commercial reference laboratory using CLSI guidelines for percent match with the SmartGene database. Drug susceptibility data can be difficult to determine and identified as *M. heckeshornense*; there was 100% identity with *M. heckeshornense* over a match length of 986 bp, while there were 36 mismatches with the next closest match, *M. xenopi*. The identification was performed at a large commercial reference laboratory using CLSI guidelines for percent match with the SmartGene database. Drug susceptibility data can be difficult to determine and was sent for molecular identification by 16S rRNA gene sequencing. Despite strong biochemical similarity to *M. xenopi*, the isolate grew equally well at 37°C and 42°C. The isolate was sent for molecular identification by 16S rRNA gene sequencing and identified as *M. heckeshornense*; there was 100% identity with *M. heckeshornense* over a match length of 986 bp, while there were 36 mismatches with the next closest match, *M. xenopi*. The identification was performed at a large commercial reference laboratory using CLSI guidelines for percent match with the SmartGene database. Drug susceptibility data can be difficult to determine and was sent for molecular identification by 16S rRNA gene sequencing. This study identified *M. heckeshornense* as the cause of a case of AIDS-associated lumbar osteomyelitis and diskitis. In vitro drug susceptibility data can be difficult to interpret for NTM due to the knowledge that some do not predict clinical response. In vitro drug susceptibility data can be difficult to interpret for NTM due to the knowledge that some do not predict clinical response. We searched the English-language literature using Pub-Med with search term “heckeshornense” and found 15 articles and 11 cases of human infection with *M. heckeshornense* (Table 1). Interestingly, 55% of these patients were thought to be immunocompetent. Due to an aggressive clinical presentation, most cases were initially treated as reactivated *M. tuberculosis* with standard four-drug therapy, which was later modified to target *M. heckeshornense*. Given its close phylogenetic relationship to *M. xenopi*, some authors advocate treating it as such with isoniazid, rifampicin, ethambutol, and clarithromycin, with or without an initial course of streptomycin; however, as with any infection, drug interactions must be considered when therapy is being selected for individual patients (5). In vitro drug susceptibility data can be difficult to interpret for NTM due to the knowledge that some do not predict clinical response. We searched the English-language literature using Pub-Med with search term “heckeshornense” and found 15 articles and 11 cases of human infection with *M. heckeshornense* (Table 1). Interestingly, 55% of these patients were thought to be immunocompetent. Due to an aggressive clinical presentation, most cases were initially treated as reactivated *M. tuberculosis* with standard four-drug therapy, which was later modified to target *M. heckeshornense*. Given its close phylogenetic relationship to *M. xenopi*, some authors advocate treating it as such with isoniazid, rifampicin, ethambutol, and clarithromycin, with or without an initial course of streptomycin; however, as with any infection, drug interactions must be considered when therapy is being selected for individual patients (5). In vitro drug susceptibility data can be difficult to interpret for NTM due to the knowledge that some do not predict clinical response. In vitro drug susceptibility data can be difficult to interpret for NTM due to the knowledge that some do not predict clinical response. Given its close phylogenetic relationship to *M. xenopi*, some authors advocate treating it as such with isoniazid, rifampicin, ethambutol, and clarithromycin, with or without an initial course of streptomycin; however, as with any infection, drug interactions must be considered when therapy is being selected for individual patients (5). In vitro drug susceptibility data can be difficult to interpret for NTM due to the knowledge that some do not predict clinical response. In vitro drug susceptibility data can be difficult to interpret for NTM due to the knowledge that some do not predict clinical response. Given its close phylogenetic relationship to *M. xenopi*, some authors advocate treating it as such with isoniazid, rifampicin, ethambutol, and clarithromycin, with or without an initial course of streptomycin; however, as with any infection, drug interactions must be considered when therapy is being selected for individual patients (5). We searched the English-language literature using Pub-Med with search term “heckeshornense” and found 15 articles and 11 cases of human infection with *M. heckeshornense* (Table 1). Interestingly, 55% of these patients were thought to be immunocompetent. Due to an aggressive clinical presentation, most cases were initially treated as reactivated *M. tuberculosis* with standard four-drug therapy, which was later modified to target *M. heckeshornense*. Given its close phylogenetic relationship to *M. xenopi*, some authors advocate treating it as such with isoniazid, rifampicin, ethambutol, and clarithromycin, with or without an initial course of streptomycin; however, as with any infection, drug interactions must be considered when therapy is being selected for individual patients (5). We searched the English-language literature using Pub-Med with search term “heckeshornense” and found 15 articles and 11 cases of human infection with *M. heckeshornense* (Table 1). Interestingly, 55% of these patients were thought to be immunocompetent. Due to an aggressive clinical presentation, most cases were initially treated as reactivated *M. tuberculosis* with standard four-drug therapy, which was later modified to target *M. heckeshornense*. Given its close phylogenetic relationship to *M. xenopi*, some authors advocate treating it as such with isoniazid, rifampicin, ethambutol, and clarithromycin, with or without an initial course of streptomycin; however, as with any infection, drug interactions must be considered when therapy is being selected for individual patients (5).

**ACKNOWLEDGMENTS**

We thank Melissa Dull and Paul D’Antin for their initial characterization of the isolate. We thank the staff of the mycobacteriology laboratory at...
Laboratory Corporation of America for the molecular identification and the susceptibility testing of *M. heckeshornense*.

There are no conflicts of interest to report.

The views expressed in this paper are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government.

REFERENCES


